GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2) » Definitions » PB Ratio

BioLine Rx (STU:YP2) PB Ratio : 0.70 (As of Apr. 09, 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-09), BioLine Rx's share price is €4.04. BioLine Rx's Book Value per Share for the quarter that ended in Dec. 2024 was €5.77. Hence, BioLine Rx's PB Ratio of today is 0.70.

Good Sign:

BioLine Rx Ltd stock PB Ratio (=0.47) is close to 2-year low of 0.47.

The historical rank and industry rank for BioLine Rx's PB Ratio or its related term are showing as below:

STU:YP2' s PB Ratio Range Over the Past 10 Years
Min: 0.47   Med: 3.83   Max: 8.26
Current: 0.47

During the past 13 years, BioLine Rx's highest PB Ratio was 8.26. The lowest was 0.47. And the median was 3.83.

STU:YP2's PB Ratio is ranked better than
90.42% of 1284 companies
in the Biotechnology industry
Industry Median: 2.04 vs STU:YP2: 0.47

During the past 12 months, BioLine Rx's average Book Value Per Share Growth Rate was -17.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -52.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -43.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -37.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioLine Rx was 8.20% per year. The lowest was -52.60% per year. And the median was -31.80% per year.

Back to Basics: PB Ratio


BioLine Rx PB Ratio Historical Data

The historical data trend for BioLine Rx's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx PB Ratio Chart

BioLine Rx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.52 1.41 0.65 8.13 1.40

BioLine Rx Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.13 6.00 3.20 5.69 1.40

Competitive Comparison of BioLine Rx's PB Ratio

For the Biotechnology subindustry, BioLine Rx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's PB Ratio falls into.


;
;

BioLine Rx PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BioLine Rx's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=4.04/5.77
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


BioLine Rx  (STU:YP2) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BioLine Rx PB Ratio Related Terms

Thank you for viewing the detailed overview of BioLine Rx's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx Headlines

No Headlines